Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda Invests €100M in New Manufacturing Plant | Contract Pharma

What are you searching for?

Sign in
Breaking News

Takeda Invests €100M in New Manufacturing Plant

Will support global vaccine strategy and Phase III dengue vaccine candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda Pharmaceutical Co. will invest more than €100 million to build a new manufacturing plant in Singen, Germany for its dengue vaccine candidate.

“This manufacturing plant investment reinforces Takeda’s strong support for our global vaccine strategy in general, and dengue in particular. The new plant will provide millions of people with access to a medicine that addresses a huge unmet medical need. It underlines our commitment to improve the lives of people worldwide,” said Dr. Thomas Wozniewski, global manufacturing and supply officer at Takeda.

“Our colleagues in Singen have vast experience in lyophilisation technology, which is key for the manufacturing process of Takeda’s dengue vaccine finished product,” Mr. Wozniewski added. Initial construction activities will start immediately, and the facility should be ready for production in 2019.

In September, Takeda initiated the Tetravalent Immunization against Dengue Efficacy Study (TIDES), a Phase III double-blind, randomized, placebo-controlled trial, evaluating the efficacy of the vaccine candidate to protect against dengue fever. The study is also evaluating vaccine safety and immunogenicity, with two doses of the vaccine candidate or placebo.

Dr. Rajeev Venkayya, president of Takeda Vaccines, said, “This dengue vaccine production facility is another strong indication of Takeda’s long-term commitment to vaccines. The progress of the dengue TIDES clinical trial, our partnership with the Bill & Melinda Gates Foundation to eradicate polio, the recent initiation of the world’s first field efficacy trial for a norovirus vaccine, and our work with the U.S. Government to develop a Zika vaccine, together demonstrate how Takeda is dedicated to developing and providing vaccines to protect people in need wherever they are.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics